<DOC>
	<DOCNO>NCT01113931</DOCNO>
	<brief_summary>Evaluate clinical efficacy safety WC2031 200 mg tablet take orally day 7 day versus Vibramycin ( doxycycline ) 100 mg capsule take orally twice day 7 day , treatment uncomplicated urogenital Chlamydia trachomatis infection . Primary efficacy endpoint microbiological cure Day 28 . Safety assessment adverse event , change vital sign laboratory test result .</brief_summary>
	<brief_title>Treatment Chlamydia Infection Comparing WC2031 Tablets With Vibramycin</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Chlamydia Infections</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1945 year age , male female presume diagnosis urogenital C. trachomatis infection use condom sexual activity study ( enrollment thru day 28 ) Clinical diagnosis pelvic inflammatory disease epididymitis baseline Diagnosis N. gonorrhoea HIV infection Active Hepatitis B C infection Prior hysterectomy ( partial total ) Treatment antimicrobial therapy know activity urogenital C. trachomatis within 28 day enrollment</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Chlamydia</keyword>
</DOC>